Evolutec Ltd.
This article was originally published in Start Up
Executive Summary
Evolutec Ltd.'s drug discovery program harnesses the power of blood-sucking ticks and other ectoparasites-many of which can feed for weeks undetected by their host's immune system-to discover drug candidates for inflammatory and autoimmune diseases, anticoagulation, cardiovascular diseases and oncology.
You may also be interested in...
Natural Products: Providing Diversity or Drug Candidates?
There is tremendous value to be had in exploiting the pharmaceutical uses of natural products, but few companies built around natural-product platforms have enjoyed much success. To succeed, these companies shouldn't be focused on merely providing chemical diversity to the drug industry. Instead, they need to articulate how their libraries will allow them to close in, quickly and with a relatively low risk of failure, on specific drugs for specific diseases.